Activist Beretta Escalates Proxy Fight, Threatens Litigation After Ruger Board Rejects Poison Pill Waiver

summarizeSummary

Activist investor Beretta Holding S.A. publicly condemned Sturm, Ruger & Co.'s board for rejecting its request to waive the poison pill, which is blocking Beretta's $44.80/share partial tender offer, and confirmed it is exploring litigation.

check_boxKey Events

• Poison Pill Rejection

  Sturm, Ruger & Co.'s board rejected Beretta Holding's request to waive the "poison pill" rights plan, which is necessary for Beretta's partial tender offer to proceed.

• Tender Offer Blocked

  The board's refusal directly blocks Beretta's proposed $44.80 per share all-cash partial tender offer, which represents a significant premium to the company's unaffected share price.

• Litigation Threat

  Beretta Holding stated it is actively exploring all litigation options against the board and its members, reserving all rights.

• Proxy Fight Escalation

  Beretta criticized the board for "entrenched, value-destructive control" and prioritizing self-protection over shareholder value, further intensifying the proxy contest.

auto_awesomeAnalysis

This filing marks a significant escalation in the ongoing proxy battle between Beretta Holding and Sturm, Ruger & Co.'s incumbent board. Beretta's strong condemnation of the board's refusal to waive the poison pill directly impedes its premium partial tender offer, which represents a substantial premium to recent trading prices. The explicit threat of litigation and the confirmation of a meeting on April 9th indicate that the conflict is intensifying and could lead to further legal action or a forced resolution. Investors should closely monitor developments regarding the tender offer, the proxy vote, and any potential litigation, as the outcome will significantly impact the company's future ownership and strategic direction.